FREMONT, Calif., Nov. 4 /PRNewswire/ -- Scios, a Johnson & Johnson
company, today announced the appointment of George Schreiner, M.D., Ph.D., to
President, Research and Development at Scios Inc. In his new position,
Dr. Schreiner becomes a member of the Johnson & Johnson worldwide research and
development staff, representing Scios in the development of new products at
Johnson & Johnson. Dr. Schreiner retains his role as Chief Scientific and
Medical Officer at Scios.
In his new role, Dr. Schreiner gains executive management responsibilities
for Scios' innovative pipeline of drugs that are in development to address
unmet medical needs in heart disease, chronic inflammation and oncology.
"Scios is accelerating clinical development in key areas of acute medical
need," said Dr. Schreiner. "As a Johnson & Johnson company, we have access to
a valuable network of global resources that gives us the opportunity to make
an impact on an international scale with our novel compounds in development.
Few biotechnology companies can do this as readily."
Prior to joining Scios, Dr. Schreiner held leadership positions at CV
Therapeutics and faculty positions at Washington University School of Medicine
and Harvard Medical School. Through his experience as a cardiovascular disease
and inflammation expert, Dr. Schreiner gained unique perspectives on the
development and future of biotechnology, which he enjoys applying at Scios.
"Scios offers researchers the unique opportunity to take a discovery from
the bench to the clinic without the downside of seeing it sold or traded for
some other resource," said Dr. Schreiner. "At Scios, we recruit researchers
and development experts who are committed to the value of driving a discovery
from its inception to the demonstration of patient benefit. We are building a
new model of biotech that will allow us to address global health problems and
break down the research and development barriers that have traditionally stood
between different regions of the world."
About Scios
Scios Inc., a Johnson & Johnson company, is a biopharmaceutical company
headquartered in Fremont, California. Scios is developing novel treatments for
cardiovascular disease, inflammatory disease and cancer. The Company's
disease-based technology platform integrates expertise in protein biology with
computational and medicinal chemistry to identify novel targets and rationally
design small molecule compounds and peptides for markets with unmet medical
needs. For more information, visit http://www.sciosinc.com.
About George Schreiner, M.D., Ph.D.
Dr. Schreiner joined Scios in 1997 as Vice President, Cardiorenal Research
where his contributions advanced the development of therapeutics targeting
disease mechanisms identified by novel biochemical and genomic techniques. In
August 2000, Dr. Schreiner was promoted to Chief Scientific Officer of Scios,
and in October 2003, he was promoted to Chief Scientific and Medical Officer
at the company.
Dr. Schreiner received his B.A., M.D., and Ph.D. degrees from Harvard
University and Harvard Medical School, respectively. He was appointed
Assistant Professor of Medicine and Pathology at Harvard Medical School and
subsequently became an Associate Professor of Medicine and Pathology at
Washington University School of Medicine. He served as Vice President of
Medical Research and Pre-Clinical Development at CV Therapeutics prior to
taking a position with Scios. Dr. Schreiner has published extensively on the
scientific and clinical aspects of cardiovascular disease and inflammation.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Chris L. Ernst of Scios Inc.,
+1-415-710-9445; or Karin Bauer Aranaz of WeissComm Partners,
+1-415-859-3414, for Scios Inc.
|
